Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis

A technology of precursors and oxides, which is applied in the field of catalytic preparation of apalutamide intermediates for the treatment of prostate cancer, can solve the problems of high chemical activity of Raney nickel powder, increased operation difficulty, large iron-containing wastewater, etc., to achieve improved Effects of equipment utilization rate, production cost reduction, and short response time

Active Publication Date: 2018-07-24
上海奥萝拉医药科技有限公司
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This new compound made from hydroxylapatite (H2O3Si(OH)) supports nickel or cerium nitrogen complexes on its surface allows for efficient use of reducing agents like ammonia gas at very low temperatures without causing unwanted reactions such as decomposition of other chemicals. It also provides excellent activity even when exposed repeatedly during industrial applications due to long lifetimes under harsh conditions. Overall this innovation improves efficiency and effectiveness in producing various types of molecules through specific methods.

Problems solved by technology

This patented technical problem addressed in this Patents relates to improving the efficiency of producing apaloitronic compounds such as apaluteanilone or other types of drugs with specific effects against certain diseases like neurologisties caused by brain cell growth disorders called progressive suprasellar nerve degenerative disease ("PDNS").

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis
  • Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis
  • Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Preparation of hydrotalcite-supported Ni / Ce composite metal oxides:

[0044] (A) Preparation of Ni / Ce composite metal oxide:

[0045] (A-1) 10mmol Ce(NO 3 ) 3 ·6H 2 O and 40mmol Ni(NO 3 ) 2 ·6H 2 Add O into 500ml of water, heat up to 40-45°C and use a paddle stirrer to stir and dissolve to obtain a metal salt mixture;

[0046] (A-2) Add the alkaline mixed solution dropwise to the metal salt mixed solution to maintain the pH between 10.5-11.0 to generate solid particles; after the pH is stable, heat up to 60-70°C and keep stirring for 2-3 days; the alkali The mixed solution is a mixed aqueous solution of sodium hydroxide of 0.5mol / L and sodium carbonate of 0.3mol / L;

[0047] (A-3) After cooling to room temperature, filter, wash the filter cake with deionized water, and then vacuum-dry at 70-80°C to constant weight to obtain a composite metal oxide precursor;

[0048] (A-4) Calcining the composite metal oxide precursor at a high temperature of 400-450° C. in

Embodiment 2

[0064] Using Cat / 200 in Example 1 as the catalyst, the amount of catalyst, the type of hydrogen donor, and the solvent were further optimized, and the optimization process was as follows:

[0065] Substrate 2-cyano-3-trifluoromethyl-5-nitropyridine (10mmol, 2.17g), catalyst Cat / 200 (0.05-0.4 times the substrate weight), 20ml solvent and hydrogen donor 60mmol at 50 Magnetic stirring reaction at -60°C, the reaction solution was taken every 1h for HPLC detection, and the reaction effect of the statistical system (reaction time, conversion rate of substrate 2-cyano-3-trifluoromethyl-5-nitropyridine and The selectivity of its target product), see shown in table 2:

[0066] Table 2 Optimization of nitro reduction reaction

[0067]

[0068]

[0069] Note: a, the amount of Cat / 200 means that the amount of Cat / 200 added is a multiple of the amount of substrate added; the low selectivity in b is due to the transition state of some nitro groups reduced to amino groups, such a

Embodiment 3

[0072] After the reaction system was determined, the catalytic system was scaled up at the level of 100 grams, and the steps were as follows:

[0073] S1: Add 2.5L of isopropanol to a 5L double-layer glass reactor with a paddle stirrer, and add 2-cyano-3-trifluoromethyl-5-nitropyridine (217g, 1mol) under nitrogen protection , catalyst Cat / 200 (43.4g, 20%wt);

[0074] S2: Turn on the stirring and control the rotation speed to 200rpm, then raise the temperature to 50-60°C at a heating rate of 2°C / min, and when the temperature reaches 55°C, the heat preservation timer will react;

[0075] S3: After the timing reaction for 2 hours, take the reaction solution and carry out HPLC detection (result: the conversion rate is 89.2%, and the selectivity is 92.3%), continue the insulation reaction for 1 hour, and take the reaction solution for HPLC detection (the conversion rate is 99.8%, and the selectivity is 96.3%) );

[0076] S4: naturally cool down to room temperature, and then filt

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a method for preparing an apalutamide intermediate as a drug for treating prostate cancer through catalysis. According to the method, Ce(NO3)3.6H2O and Ni(NO3)2.6H2O serve as a Ce source and a Ni source to prepare a Ni/Ce compound metal oxide, Mg(NO3)2.6H2O and Al(NO3)2.9H2O serve as a magnesium source and an aluminum source to prepare magnalium aluminum hydrotalcite, and the Ni/Ce compound metal oxide, which serves an active ingredient, is in situ loaded onto a surface of the magnalium aluminum hydrotalciteand/or into a layered cavity when a coprecipitation method is used for preparing the magnalium aluminum hydrotalcite. The prepared Ni/Ce compound metal oxide loaded on the hydrotalcite can be used forcatalyzing 2-cyano-3-trifluoromethyl-5-nitropyridine to generate the apalutamide intermediate 2-cyano-3-trifluoromethyl-5-aminopyridine as the drug for treating the prostate cancer. The catalytic system of the invention is high in yield, and the target product is good in selectivity.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner 上海奥萝拉医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products